DUBLIN--(BUSINESS WIRE)--The "Global Paediatric Vaccine Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 - 2023" report has been added to Research and Markets' offering.
Pediatric vaccines are given to a children in its age from 0 - 18 years of age. Congenital Zika is one of the latest pediatric vaccine which found relation in devastating defects in infants and Zika virus. This leads to contribute in the growth of the pediatric vaccine market with a CAGR of approx 15.65% during forecast period 2016-2023.
The global pediatric vaccine market is driven by increasing government focus on immunization programs, increase in the number of disease among children such as TB, Hepatitis etc. and government funding for the vaccine development. High growth of healthcare sector globally and increase in the expenditure in health industry are the opportunity for the players involved in the pediatricpaedaitic vaccine market to grow.
However, huge capital investment and stringent government regulation for the development of new vaccines and standards to be followed by government regarding pediatric vaccine is hampering the demand of the pediatric vaccine market. The major challenge faced by pediatric vaccine market are vaccine cost and inadequate access to vaccine.
- Pfizer, Inc. (U.S.)
- Glaxosmithkline, Plc. (U.K.)
- Merck & Co., Inc. (U.S.)
- Sanofi Pasteur (France)
- Emergent Biosolutions, Inc. (U.S.)
- Johnson & Johnson (India)
- Medimmune, Llc (U.S.)
- Astellas Pharma Inc. (Japan)
- Serum Institute of India (India)
- Zydua Cadila (India)
- Emergent Biosolutions Inc. (U.S.)
- Mitsubishi Tanabe Pharma. (Japan)
- Takeda Pharmaceutical (Japan)
- Sinovac Biotech (China)
Key Topics Covered:
2. Market Overview
3. Market Determinants
4. Market Segmentation
5. Competitive Landscape
6. Geographical Analysis
7. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/fqkt55/global_paediatric